Lakefront Biotherapeutics (LKFT) Receivables (2013 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Receivables for 13 consecutive years, with $63.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables fell 27.97% year-over-year to $63.3 million; the TTM figure through Mar 2026 stood at $63.3 million (down 27.97% YoY), while the FY2025 annual figure was $60.4 million, down 1.88% from the prior year.
• Receivables improved to $63.3 million in Q1 2026 per LKFT's latest filing, from $60.4 million in the prior quarter.
• Across five years, Receivables topped out at $100.0 million in Q1 2024 and bottomed at $36.2 million in Q4 2023.
• Historically, Receivables has averaged $75.8 million across 5 years, with a median of $79.5 million in 2023.
• Annual changes were most pronounced in 2022 — Receivables sank 65.24% — and 2024, when it jumped 70.13%.
• Lakefront Biotherapeutics' Receivables stood at $49.3 million in 2022, then declined by 26.54% to $36.2 million in 2023, then surged by 70.13% to $61.6 million in 2024, then retreated by 1.88% to $60.4 million in 2025, then grew by 4.68% to $63.3 million in 2026.
• Business Quant data shows LKFT's Receivables at $63.3 million in Q1 2026, $60.4 million in Q4 2025, and $90.8 million in Q3 2025.